National Research Corporation  (NRC)
Other Ticker:  
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
Price: $46.5300 $-0.25 -0.534%
Day's High: $47.25 Week Perf: 1.04 %
Day's Low: $ 46.21 30 Day Perf: 10.9 %
Volume (M): 30 52 Wk High: $ 47.60
Volume (M$): $ 1,396 52 Wk Avg: $42.50
Open: $47.02 52 Wk Low: $34.69

 Market Capitalization (Millions $) 1,150
 Shares Outstanding (Millions) 25
 Employees -
 Revenues (TTM) (Millions $) 148
 Net Income (TTM) (Millions $) 29
 Cash Flow (TTM) (Millions $) -10
 Capital Exp. (TTM) (Millions $) 13

National Research Corporation
The National Research Corporation (NRC) is a healthcare performance improvement company headquartered in Lincoln, Nebraska, United States. The company was founded in 1981 by Michael Hays and Richard L. Bjorklund, with the aim of providing healthcare organizations with valuable data and insights to improve quality of care, patient experience, and financial performance. The company's mission is to enable healthcare organizations to provide better patient-centered care and improve their overall performance through an extensive suite of performance improvement solutions.

The NRC has established itself as a leading provider of healthcare performance measurement, analytics, and improvement solutions. The company's services cover all aspects of the healthcare industry, including hospitals, long-term care settings, home health and hospice, and ambulatory care facilities. It provides a range of products and services such as quality measurement surveys, patient experience surveys, market insights and patient satisfaction assessments, workforce engagement tools, care transitions solutions, and an online rating and review platform.

The NRC's quality measurement surveys are designed to help organizations assess their clinical and operational performance across various domains, including patient safety, clinical outcomes, care coordination, and patient experience. The patient experience surveys provided by the NRC are aimed at gathering feedback from patients regarding their care experiences and interactions with healthcare providers, and these surveys are widely used by hospitals and other healthcare facilities to improve communication, care coordination, and patient satisfaction.

In addition, the NRC provides market insights and patient satisfaction assessments to help healthcare organizations identify opportunities for growth and service expansion. The company's workforce engagement tools help healthcare organizations improve staff morale and retain their top-performing employees through insights and analytics on employee satisfaction and engagement. The care transitions solutions provided by the NRC help healthcare organizations improve the safety and effectiveness of care transitions for patients moving between care settings, minimizing the risk of adverse events.

Furthermore, the NRC has an online rating and review platform ' MyExperience.com ' that allows patients to rate and review healthcare facilities, thus providing healthcare organizations with valuable insight into the needs and preferences of patients in their communities. The platform also allows healthcare organizations to respond to patient feedback, improving transparency, and communication with patients.

Overall, the National Research Corporation is dedicated to providing healthcare organizations with the information they need to improve the quality of care they provide, enhance the patient experience, and improve financial performance. Through a range of products and services, the NRC empowers healthcare organizations to provide better patient-centered care, resulting in improved health outcomes and better overall performance.

   Company Address: 1245 Q Street Lincoln 68508 NE
   Company Phone Number: 475-2525   Stock Exchange / Ticker: NASDAQ NRC
   NRC is expected to report next financial results on November 03, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Aclarion Inc

Aclarion Inc's Performance in Q2 2023 Raises Concerns Despite Impressive Revenue Growth

In this bearish article, we will examine Aclarion Inc's financial performance, primarily focusing on the financial time-frame closing on June 30, 2023, and its implications for the company's future. Despite an impressive revenue growth of 59.91%, there are underlying concerns that cannot be ignored. Additionally, recent trading activity and the stock's year-to-date performance indicate a declining trend. This article aims to highlight and explain these issues.
Financial Results and Revenue Growth:
Aclarion Inc showcased balanced books of $0.00 per share for the financial time-frame closing June 30, 2023. While this might initially seem positive from a profitability standpoint, it is vital to note that it remains unchanged both from the previous year and the prior reporting season. This stagnant performance raises concerns about Aclarion's ability to generate consistent profits.

Delwinds Insurance Acquisition Corp

Delwinds Insurance Acquisition Corp Reports Revenue of $0.012 Million in Q2 2023

Medical Laboratories Company Reports Modest Revenue in Q2 2023 Earnings Season
In the latest quarterly financial report released by the Medical Laboratories company, it has been revealed that the company generated revenue amounting to $0.012 million during the second quarter of the 2023 earnings season. While this figure may seem modest, it reflects the company's ongoing efforts to navigate the challenging market conditions currently impacting the healthcare industry.
Despite the relatively low revenue, Medical Laboratories remains focused on its core competencies and continues to deliver quality services to its clients. The company's strong reputation in the market has allowed it to maintain a steady stream of business, despite the headwinds it faces.

Invitae Corporation

Battling Strong Headwinds, Invitae Corporation Powers Through to Deliver Stellar Q2 2023 Earnings

Invitae Corporation, a prominent player in the Medical Laboratories sector, reported disappointing financial results for the April to June 30 2023 time-frame. The company's earnings per share (EPS) declined to $-0.78, compared to $-10.87 a year earlier, representing a significant increase in losses. Furthermore, revenue plummeted by 11.777% to $120.53 million from $136.62 million in the prior year, while sequentially increasing by a meager 2.706% from $117.36 million.
Revenue Contrast
Contrasting with the growth observed in the remainder of the Medical Laboratories sector, which recorded a revenue increase of 3.98% in the second quarter of 2023 compared to the same reporting period a year ago, Invitae Corporation suffered a substantial decrease in revenue. This decline puts the company at a clear disadvantage within its industry, indicating a failure to adapt to current market trends and potential internal inefficiencies.

Bionexus Gene Lab Corp

Bionexus Gene Lab Corp Reports Modest Growth in Top-line Revenue during Fiscal Q2 2023

Bionexus Gene Lab Corp (BGLC) recently released its financial results for the second quarter of 2023. In order to understand the implications of these results and their potential effects on the company's future, it is crucial to delve deeper into the figures and analyze them in the context of the overall medical laboratories sector.
Revenue Growth and Comparison:
During the second quarter of 2023, BGLC's revenue witnessed a slight increase of 3.289% to reach $2.57 million. This should be seen in relation to the corresponding period a year earlier, when the company generated $2.49 million in revenue. Furthermore, Q2 2023 revenue also recorded a sequential growth of 7.978% from $2.38 million.

Biocept Inc

Biocept Inc's Second Quarter 2023 Report Reveals Shocking -94.449% Drop in Revenue: a Critical Concern for the Medical Laboratories Sector

Biocept Inc (BIOC) has recently released its second-quarter financial report for 2023, and the results are disastrous. The company's revenue plummeted by a staggering -94.449% to a mere $0.59 million. This significant decline in revenue is alarming, especially when compared to the rest of the Medical Laboratories sector, which experienced revenue growth during the same period.
Furthermore, the company's shortfall per share has widened to $-3.50, a considerable deterioration from the previous year's reporting season. In comparison to the prior reporting season, revenue deteriorated sequentially by -12.481% from $0.67 million.


National Research's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com